Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 45: 526-531, 1999;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Colford, J. W.
Right arrow Articles by Langman, C. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Colford, J. W.
Right arrow Articles by Langman, C. B.
Related Collections
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 1999;45:526-531.)
© 1999 American Association for Clinical Chemistry, Inc.

Articles

Immunoradiometric Assay for Intact Human Osteocalcin(1–49) without Cross-Reactivity to Breakdown Products

John W. Colford1,1, Bruce A. Lueddecke1, Michael Salvati1, Dave Hanna1,a, Dawn Sailer2, Sundeep Khosla3, B. Lawrence Riggs3 and Craig B. Langman2

1 DiaSorin Inc., Stillwater, MN 55082.

2 Northwestern Medical School and Children's Memorial Hospital, Division of Nephrology and Mineral Metabolism, Chicago, IL 60611.

3 Mayo Clinic and Foundation, Division of Endocrinology/Metabolism, Rochester, MN 55902.
a Address correspondence to this author at: DiaSorin Inc., P.O. Box 285, 1990 Industrial Blvd., Stillwater, MN.

Background: Osteocalcin (Oc), a serum marker of bone turnover, circulates in several forms. We developed an assay for intact human Oc and investigated its clinical features.

Methods: We generated goat antibodies and N- and C-terminal Oc. The former was used on solid phase (polystyrene beads), and the latter was used as the tracer in an IRMA.

Results: The assay was linear with no cross-reactivity to Oc(1–43), total imprecision (CV) of <10%, and recovery of 100% ± 10%. Assay values for intact Oc in EDTA plasma samples were unchanged at 18–25 °C for 6 h. Values for intact Oc in serum, EDTA plasma, and heparin plasma samples did not change after storage on ice for 8 h. Serum samples from patients with various conditions were stored at -70 or -135 °C for up to 5 years and yielded z-scores comparable to an Oc(1-43) IRMA for all conditions except for renal failure. In renal failure, the Oc(1–43) assay values were increased, whereas the intact assay values were in the reference interval.

Conclusion: Decreases in Oc assay values are inhibited by calcium chelation, and slowed by reduced temperatures. The described assay for intact Oc allows improved specificity for bone compared with an assay for Oc(1–43).© 1999 American Association for Clinical Chemistry






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Association for Clinical Chemistry.